1. Home
  2. WBX vs MREO Comparison

WBX vs MREO Comparison

Compare WBX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wallbox N.V.

WBX

Wallbox N.V.

HOLD

Current Price

$3.23

Market Cap

50.6M

ML Signal

HOLD

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

HOLD

Current Price

$0.28

Market Cap

52.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WBX
MREO
Founded
2015
2015
Country
Spain
United Kingdom
Employees
696
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
52.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
WBX
MREO
Price
$3.23
$0.28
Analyst Decision
Buy
Buy
Analyst Count
4
5
Target Price
$4.75
$1.50
AVG Volume (30 Days)
19.0K
1.6M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.67
EPS
N/A
N/A
Revenue
N/A
$500,000.00
Revenue This Year
$18.10
$5,184.20
Revenue Next Year
$94.11
$55.51
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.20
52 Week High
$7.83
$2.94

Technical Indicators

Market Signals
Indicator
WBX
MREO
Relative Strength Index (RSI) 61.85 30.21
Support Level $2.84 $0.20
Resistance Level $3.26 $0.36
Average True Range (ATR) 0.21 0.02
MACD 0.03 -0.00
Stochastic Oscillator 91.86 17.39

Price Performance

Historical Comparison
WBX
MREO

About WBX Wallbox N.V.

Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: